These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 26077415)

  • 1. Incidence and Management of Infusion Reactions to Infliximab in a Prospective Real-world Community Registry.
    Choquette D; Faraawi R; Chow A; Rodrigues J; Bensen WJ; Nantel F
    J Rheumatol; 2015 Jul; 42(7):1105-11. PubMed ID: 26077415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Premedication prevents infusion reactions and improves retention rate during infliximab treatment.
    Bartoli F; Bruni C; Cometi L; Blagojevic J; Fiori G; Tofani L; Galluccio F; Furst DE; Matucci Cerinic M
    Clin Rheumatol; 2016 Nov; 35(11):2841-2845. PubMed ID: 27436188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Premedication with intravenous steroids does not influence the incidence of infusion reactions following infliximab infusions in pediatric inflammatory bowel disease patients-a case-control study.
    van Wassenaer EA; Meester VL; Kindermann A; Koot BGP; Benninga MA; de Meij TGJ
    Eur J Clin Pharmacol; 2019 Oct; 75(10):1445-1450. PubMed ID: 31332475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab in pediatric rheumatology patients: a retrospective analysis of infusion reactions and severe adverse events during 2246 infusions over 12 years.
    Aeschlimann FA; Hofer KD; Cannizzaro Schneider E; Schroeder S; Lauener R; Saurenmann RK
    J Rheumatol; 2014 Jul; 41(7):1409-15. PubMed ID: 24833759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the safety and satisfaction of rheumatic patients with accelerated infliximab infusion.
    de Carvalho JF; Dos Santos MNP; de Oliveira JMV; Lanty Silva ANS; de Araujo RPC; Cardozo JB
    Adv Rheumatol; 2018 Aug; 58(1):22. PubMed ID: 30657070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry.
    Mok CC; Chan KY; Lee KL; Tam LS; Lee KW;
    Int J Rheum Dis; 2014 Dec; 17 Suppl 3():1-8. PubMed ID: 24382315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Premedication Use in Preventing Acute Infliximab Infusion Reactions in Patients with Inflammatory Bowel Disease: A Single Center Cohort Study.
    Gold SL; Cohen-Mekelburg S; Schneider Y; Shen N; Faggen A; Rupert A; Scherl EJ; Bosworth B; Steinlauf A
    Inflamm Bowel Dis; 2017 Oct; 23(10):1882-1889. PubMed ID: 28837521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The incidence and management of infusion reactions to infliximab: a large center experience.
    Cheifetz A; Smedley M; Martin S; Reiter M; Leone G; Mayer L; Plevy S
    Am J Gastroenterol; 2003 Jun; 98(6):1315-24. PubMed ID: 12818276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A real-world, multi-site, observational study of infusion time and treatment satisfaction with rheumatoid arthritis patients treated with intravenous golimumab or infliximab.
    Daniel SR; McDermott JD; Le C; Pierce CA; Ziskind MA; Ellis LA
    J Med Econ; 2018 Jul; 21(7):724-731. PubMed ID: 29718743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Incidence and management of infusion reactions to infliximab in 186 italian patients with rheumatoid arthritis: the Padua experience].
    Botsios C; Ostuni P; Todesco S
    Reumatismo; 2005; 57(1):44-51. PubMed ID: 15776146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis.
    Sany J; Kaiser MJ; Jorgensen C; Trape G
    Ann Rheum Dis; 2005 Nov; 64(11):1647-9. PubMed ID: 16227416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of infliximab treatment in patients with rheumatoid arthritis in a real-world clinical setting: description and evaluation of infusion reactions.
    Kelsall J; Rogers P; Galindo G; De Vera MA
    J Rheumatol; 2012 Aug; 39(8):1539-45. PubMed ID: 22589260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number.
    Wasserman MJ; Weber DA; Guthrie JA; Bykerk VP; Lee P; Keystone EC
    J Rheumatol; 2004 Oct; 31(10):1912-7. PubMed ID: 15468353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [PREMEDICATION WITH CORTICOSTEROIDS PRIOR TO IV INFLIXIMAB - A COMPARISON BETWEEN INFLAMMATORY BOWEL DISEASE (IBD) AND RHEUMATIC PATIENTS].
    Oshri D; Schwarz D; Vodonos A; Zimhony N; Abu-Shakra M; Zeller L
    Harefuah; 2019 Sep; 158(9):571-575. PubMed ID: 31507106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of antitumour necrosis factor treatments in chronic rheumatic diseases: therapy discontinuations related to side effects.
    Varela H; Villamañán E; Plasencia C; Romero JA; Ruano M; Balsa A; Herrero A
    J Clin Pharm Ther; 2016 Jun; 41(3):306-9. PubMed ID: 27191537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab in inflammatory bowel disease. Is premedication necessary?
    Nuñez F P; Quera R; Simian D; Flores L; Figueroa C; Ibañez P; Kronberg U; Lubascher J; Pizarro G
    Gastroenterol Hepatol; 2021 May; 44(5):321-329. PubMed ID: 33386199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of acute adverse events related to infliximab infusions in pediatric patients.
    Lahdenne P; Wikström AM; Aalto K; Kolho KL
    Arthritis Care Res (Hoboken); 2010 Jun; 62(6):785-90. PubMed ID: 20535789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Premedication as primary prophylaxis does not influence the risk of acute infliximab infusion reactions in immune-mediated inflammatory diseases: A systematic review and meta-analysis.
    Fumery M; Tilmant M; Yzet C; Brazier F; Loreau J; Turpin J; Le Mouel JP; Goeb V; Nguyen-Khac E; Singh S; Dupas JL; Diouf M
    Dig Liver Dis; 2019 Apr; 51(4):484-488. PubMed ID: 30686715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infusion reactions during infliximab treatment are not associated with IgE anti-infliximab antibodies.
    van Schie KA; Ooijevaar-De Heer P; Kruithof S; Plasencia C; Jurado T; Pascual Salcedo D; Brandse JF; d'Haens GR; Wolbink GJ; Rispens T
    Ann Rheum Dis; 2017 Jul; 76(7):1285-1288. PubMed ID: 28455438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab in patients with psoriasis and other inflammatory diseases: evaluation of adverse events in the treatment of 168 patients.
    Antonio JR; Sanmiguel J; Cagnon GV; Augusto MS; Godoy MF; Pozetti EM
    An Bras Dermatol; 2016; 91(3):306-10. PubMed ID: 27438197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.